Solara Active Pharma Sciences Limited
NSE: SOLARA · Pharmaceuticals
Snapshot
Unlock Solara Active Pharma Sciences Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Solara Active Pharma Sciences Limited is an Indian pharmaceutical company specialising in the manufacturing and distribution of a wide range of Active Pharmaceutical Ingredients (APIs). The company also provides comprehensive contract research and manufacturing services, including analytical support and impurity synthesis for global clients.
Business Model
The company generates revenue through the large-scale production and sale of APIs across diverse therapeutic categories, alongside providing contract development and manufacturing services (CDMO). It leverages global export channels to supply international markets across the Asia Pacific, Europe, and the Americas.
Growth Outlook
Growth is driven by the expansion of its CDMO service offerings and the continued demand for its extensive portfolio of APIs in international markets. The company focuses on leveraging its regulatory support capabilities to strengthen partnerships with global pharmaceutical firms.
Key Risks
- Regulatory Compliance. The company faces significant risks related to stringent international quality standards and potential inspections by global health authorities like the USFDA.
- Raw Material Price Volatility. Fluctuations in the cost of key starting materials and intermediates can adversely impact profit margins in the API manufacturing business.
- Foreign Exchange Risk. As a significant exporter, the company is exposed to currency fluctuations that may affect its competitive pricing and reported earnings.
- Competitive Pressure. The API sector is highly fragmented and competitive, requiring constant investment in R&D and process efficiency to maintain market share.
Start your research today
Unlock AI insights, financials, peers and live data on Solara Active Pharma Sciences Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹1,535 Cr
TTM · consolidated
NET PROFIT
₹37 Cr
TTM · consolidated
EPS
₹7.66
TTM · consolidated
RETURN ON EQUITY
2.7%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
8.1%
TTM · consolidated
P/E
83.3×
Q2 FY27 · consolidated
EV/EBITDA
14.9x
Q2 FY27 · consolidated
EBITDA MARGIN
15.7%
TTM · consolidated
NET PROFIT MARGIN
6.8%
Q2 FY27 · consolidated
DEBT TO EQUITY
0.4x
Q2 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Solara Active Pharma Sciences LimitedSOLARA | ₹3,068 Cr | 83.3× | 14.95 | 27.3% | 15.7% | 2.7% | 8.1% | +6.4% |
Kwality Pharmaceuticals LimitedKPL | ₹3,648 Cr | 45.0× | 27.34 | 37.9% | 24.9% | 27.2% | 36.4% | +293.6% |
Unichem Laboratories LimitedUNICHEMLAB | ₹3,547 Cr | 11.4× | 12.40 | 9.4% | 13.0% | 11.8% | 14.1% | +7.0% |
Shukra Pharmaceuticals LimitedSHUKRAPHAR | ₹3,513 Cr | 88.8× | 66.74 | 115.0% | 70.3% | 51.7% | 59.7% | +94.8% |
Ind-Swift Laboratories LimitedINDSWFTLAB | ₹3,072 Cr | 36.2× | 18.50 | 66.4% | 19.8% | 6.0% | 7.4% | +243.9% |
HikalHIKAL | ₹2,722 Cr | -80.6× | 13.83 | -5.4% | 14.1% | -2.7% | 0.1% | -7.4% |
As of Q2 FY27
Financials
Solara Active Pharma Sciences Limited
NSE: SOLARA · Pharmaceuticals
Snapshot
Unlock Solara Active Pharma Sciences Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Solara Active Pharma Sciences Limited is an Indian pharmaceutical company specialising in the manufacturing and distribution of a wide range of Active Pharmaceutical Ingredients (APIs). The company also provides comprehensive contract research and manufacturing services, including analytical support and impurity synthesis for global clients.
Business Model
The company generates revenue through the large-scale production and sale of APIs across diverse therapeutic categories, alongside providing contract development and manufacturing services (CDMO). It leverages global export channels to supply international markets across the Asia Pacific, Europe, and the Americas.
Growth Outlook
Growth is driven by the expansion of its CDMO service offerings and the continued demand for its extensive portfolio of APIs in international markets. The company focuses on leveraging its regulatory support capabilities to strengthen partnerships with global pharmaceutical firms.
Key Risks
- Regulatory Compliance. The company faces significant risks related to stringent international quality standards and potential inspections by global health authorities like the USFDA.
- Raw Material Price Volatility. Fluctuations in the cost of key starting materials and intermediates can adversely impact profit margins in the API manufacturing business.
- Foreign Exchange Risk. As a significant exporter, the company is exposed to currency fluctuations that may affect its competitive pricing and reported earnings.
- Competitive Pressure. The API sector is highly fragmented and competitive, requiring constant investment in R&D and process efficiency to maintain market share.
Start your research today
Unlock AI insights, financials, peers and live data on Solara Active Pharma Sciences Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹1,535 Cr
TTM · consolidated
NET PROFIT
₹37 Cr
TTM · consolidated
EPS
₹7.66
TTM · consolidated
RETURN ON EQUITY
2.7%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
8.1%
TTM · consolidated
P/E
83.3x
Q2 FY27 · consolidated
EV/EBITDA
14.9x
Q2 FY27 · consolidated
EBITDA MARGIN
15.7%
TTM · consolidated
NET PROFIT MARGIN
6.8%
Q2 FY27 · consolidated
DEBT TO EQUITY
0.4x
Q2 FY27 · consolidated
Peers · Pharmaceuticals
As of Q2 FY27